UK pharmaceutical businesses: R&D expenditure 2002-2017

This statistic shows expenditure on research and development by UK businesses operating in the pharmaceutical industry from 2002 to 2017. In 2017, expenditure on R&D amounted to approximately 4.3 billion British pounds, a slight decrease from previous year.

Research and development expenditure of pharmaceutical businesses in the United Kingdom (UK) from 2002 to 2017

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
in the first 12 months
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

November 2018

Region

United Kingdom

Survey time period

2002 to 2017

Number of respondents

5,500*

Special properties

Businesses known to perform R&D

Method of interview

Questionnaire

Supplementary notes

The data refers to business R&D performed in the UK irrespective of the residence of the ultimate owner. Overseas activities of affiliates of UK businesses are not included by the source.
* Total businesses surveyed. Breakdown by industry not provided.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Italy"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.